China National Medicines Gelecekteki Büyüme

Future kriter kontrolleri 1/6

China National Medicines kazanç ve gelirin sırasıyla yıllık 11.2% ve 10% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 11.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 13.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

11.2%

Kazanç büyüme oranı

11.2%

EPS büyüme oranı

Healthcare kazanç büyümesi	23.8%
Gelir büyüme oranı	10.0%
Gelecekteki özkaynak getirisi	13.3%
Analist kapsamı	Low
Son güncelleme	24 Oct 2024

Gelecekteki son büyüme güncellemeleri

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 25

Recent updates

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 25

China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Sep 26

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Sep 10

Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

Jul 28

China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

Jun 24

China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Jun 07

Is China National Medicines (SHSE:600511) Using Too Much Debt?

Jun 05

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

May 21

Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

Apr 10

China National Medicines (SHSE:600511) Could Easily Take On More Debt

Feb 28

Kazanç ve Gelir Büyüme Tahminleri

SHSE:600511 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	63,960	2,786	N/A	2,727	4
12/31/2025	58,523	2,510	N/A	2,207	5
12/31/2024	52,810	2,263	N/A	1,902	2
9/30/2024	51,195	2,165	1,540	1,688	N/A
6/30/2024	50,312	2,162	1,688	1,827	N/A
3/31/2024	50,592	2,191	2,008	2,151	N/A
12/31/2023	49,696	2,146	2,582	2,727	N/A
9/30/2023	47,486	1,995	2,466	2,602	N/A
6/30/2023	47,632	2,086	2,040	2,194	N/A
3/31/2023	45,665	2,005	2,429	2,560	N/A
12/31/2022	45,499	1,964	2,265	2,395	N/A
9/30/2022	46,719	1,884	1,336	1,460	N/A
6/30/2022	46,399	1,850	1,081	1,185	N/A
3/31/2022	47,185	1,830	1,746	1,851	N/A
12/31/2021	46,469	1,754	1,862	1,957	N/A
9/30/2021	45,559	1,680	1,085	1,170	N/A
6/30/2021	44,923	1,529	1,129	1,197	N/A
3/31/2021	42,512	1,449	1,187	1,247	N/A
12/31/2020	40,379	1,383	1,233	1,302	N/A
9/30/2020	41,046	1,537	1,058	1,125	N/A
6/30/2020	41,153	1,469	1,922	1,997	N/A
3/31/2020	42,805	1,549	1,399	1,477	N/A
12/31/2019	44,644	1,604	1,690	1,776	N/A
9/30/2019	42,673	1,525	1,037	1,139	N/A
6/30/2019	40,991	1,523	1,024	1,159	N/A
3/31/2019	39,659	1,436	-33	103	N/A
12/31/2018	38,740	1,404	849	982	N/A
9/30/2018	37,994	1,256	2,457	2,576	N/A
6/30/2018	37,452	1,224	N/A	2,058	N/A
3/31/2018	36,653	1,163	N/A	1,424	N/A
12/31/2017	36,285	1,141	N/A	1,074	N/A
9/30/2017	36,072	1,060	N/A	63	N/A
6/30/2017	35,540	1,044	N/A	-85	N/A
3/31/2017	40,103	1,101	N/A	488	N/A
12/31/2016	34,611	990	N/A	1,043	N/A
9/30/2016	28,613	887	N/A	461	N/A
6/30/2016	22,813	752	N/A	716	N/A
3/31/2016	12,408	527	N/A	445	N/A
12/31/2015	12,078	513	N/A	440	N/A
9/30/2015	12,065	499	N/A	307	N/A
6/30/2015	11,894	499	N/A	424	N/A
3/31/2015	11,773	490	N/A	394	N/A
12/31/2014	11,538	483	N/A	219	N/A
9/30/2014	11,177	465	N/A	338	N/A
6/30/2014	10,824	457	N/A	240	N/A
3/31/2014	10,408	431	N/A	204	N/A
12/31/2013	10,081	412	N/A	186	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 600511 'nin tahmini kazanç büyümesi (yıllık 11.2% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 600511 şirketinin kazançlarının (yıllık 11.2% ) CN pazarından (yıllık 26.1% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 600511 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 600511 şirketinin gelirinin (yıllık 10% ) CN pazarından (yıllık 14% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 600511 şirketinin gelirinin (yıllık 10% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 600511 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 13.3 %).

China National Medicines Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Price target increased by 14% to CN¥46.58

Price target decreased to CN¥39.20

Recent updates

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Third quarter 2024 earnings released: EPS: CN¥0.64 (vs CN¥0.63 in 3Q 2023)

China National Medicines Corporation Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 16%

China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Now 22% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: CN¥0.72 (vs CN¥0.76 in 2Q 2023)

Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

China National Medicines Corporation Ltd. to Report First Half, 2024 Results on Aug 22, 2024

China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

Now 20% undervalued

China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Dividend increased to CN¥0.85

Is China National Medicines (SHSE:600511) Using Too Much Debt?

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

First quarter 2024 earnings released: EPS: CN¥0.61 (vs CN¥0.55 in 1Q 2023)

Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

China National Medicines Corporation Ltd. to Report Q1, 2024 Results on Apr 26, 2024

China National Medicines Corporation Ltd., Annual General Meeting, Apr 25, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

China National Medicines (SHSE:600511) Could Easily Take On More Debt

China National Medicines Corporation Ltd. to Report Fiscal Year 2023 Results on Mar 21, 2024

Third quarter 2023 earnings released: EPS: CN¥0.63 (vs CN¥0.76 in 3Q 2022)

China National Medicines Corporation Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: CN¥0.76 (vs CN¥0.65 in 2Q 2022)

Price target increased by 14% to CN¥46.58

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.76 (vs CN¥0.71 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.65 (vs CN¥0.62 in 2Q 2021)

China National Medicines Corporation Ltd.(XSSC:600511) dropped from S&P Global BMI Index

China National Medicines Corporation Ltd.(XSSC:600511) dropped from FTSE All-World Index (USD)

Price target decreased to CN¥39.20

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Now 23% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥0.71 (vs CN¥0.51 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.62 (vs CN¥0.51 in 2Q 2020)

Upcoming dividend of CN¥0.55 per share

First quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.31 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.83 (vs CN¥2.11 in FY 2019)

New 90-day low: CN¥36.33

New 90-day low: CN¥41.32

China National Medicines Corporation Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

China National Medicines Corporation Ltd. Announces Resignation of Li Hui as A Director, the General Manager, A Member of the Strategy Committee and A Member of the Audit Committee

Investor sentiment deteriorated over the past week

Market bids up stock over the past week

New 90-day high: CN¥50.10

Third quarter earnings released

China National Medicines Corporation Ltd. to Report Q3, 2020 Results on Oct 22, 2020

Earnings released

New 90-day high - CN¥52.00

China National Medicines Corporation Ltd. to Report First Half, 2020 Results on Aug 19, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin